A practical reference on NAD+ salvage: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-03-07 and is reviewed periodically as new material appears.
Natural sources of NMN include mammals, plants, and microorganisms, where it functions as an intermediate in NAD+ salvage and biosynthesis pathways. In mammals, the enzyme nicotinamide phosphoribosyltransferase produces NMN from nicotinamide and phosphoribosyl pyrophosphate. NMN is then converted to NAD+ by nicotinamide mononucleotide adenylyltransferase. Some foods contain measurable NMN, but reported amounts vary widely by species, tissue, and analytical method. The extent to which dietary NMN contributes to cellular NAD+ pools remains an open research question.
Chemically, NMN is described by the molecular formula C11H15N2O8P and a molecular mass near 334.22 g/mol. The beta anomer has a CAS Registry Number of 1094-61-7. It is typically supplied as a white to off-white powder for laboratory use. The molecule carries a phosphate group and a positively charged nicotinamide ring, giving it polar and water-soluble character. These properties influence how it is detected, purified, and stored in research and analytical laboratories.
Nicotinamide mononucleotide, abbreviated NMN, is a naturally occurring nucleotide. Its structure combines a nicotinamide base with a ribose sugar and a phosphate group. Within cells, NMN sits on the biosynthetic route that recycles nicotinamide back into nicotinamide adenine dinucleotide, or NAD+. Because NAD+ participates in redox reactions and signaling, enzymes that produce and consume it influence many metabolic processes. The compound is therefore best described as an intermediate rather than a final signaling molecule.
In the canonical salvage pathway, nicotinamide phosphoribosyltransferase, known as NAMPT, transfers a phosphoribosyl group to nicotinamide and releases NMN. A second enzyme, NMN adenylyltransferase, then attaches an adenylyl group to NMN to form NAD+. Alternative routes exist, including a pathway that uses nicotinamide riboside and its phosphorylated forms. The relative contribution of extracellular NMN to intracellular NAD+ pools remains an area of active investigation, and the roles of specific transporters and enzymes are not completely defined.
| Property | Value | Notes |
|---|---|---|
| Common name | Nicotinamide mononucleotide | Often abbreviated NMN |
| Chemical formula | C11H15N2O8P | Beta anomer form |
| Molecular mass | 334.22 g/mol | Calculated from formula |
| CAS Registry Number | 1094-61-7 | Beta-NMN |
| Appearance | White to off-white powder | Typical laboratory grade |
Nicotinamide mononucleotide, abbreviated NMN, is a naturally occurring nucleotide found in the cells of many organisms, including bacteria, plants, and mammals. Its structure consists of a nicotinamide ring attached to a ribose-phosphate group. NMN functions as an intermediate in the NAD+ salvage pathway, a recycling route that regenerates nicotinamide adenine dinucleotide. The enzyme nicotinamide phosphoribosyltransferase produces NMN from nicotinamide and phosphoribosyl pyrophosphate. A second enzyme, NMN adenylyltransferase, then converts NMN into NAD+.
Dietary sources of NMN include small amounts in certain vegetables, fruits, and other foods, although exact values vary by sample and method. Endogenous NMN concentrations are tightly regulated and often low, making measurement in blood or tissues technically demanding. After oral intake, NMN is thought to be rapidly metabolized in the intestine and liver, and intact NMN may not reach all tissues at high levels. Some rodent studies report increases in tissue NAD+ after oral NMN, while human data remain limited and sometimes rely on blood NAD+ metabolites rather than direct tissue measures.
Research on NMN has focused on aging, metabolic regulation, exercise capacity, and insulin sensitivity, but findings are preliminary. Many human trials are small, short in duration, and use different endpoints, which complicates comparison across studies. No national regulator has approved NMN as a therapeutic drug for any indication. In some countries it is sold as a supplement or research chemical, while other jurisdictions have questioned its status under food or supplement laws. Claims about extending human lifespan or reversing aging are not supported by established clinical evidence.
Nicotinamide mononucleotide, usually shortened to NMN, is a naturally occurring nucleotide. Its structure consists of a nicotinamide base linked to a ribose sugar that carries a phosphate group. In cells, NMN serves as an intermediate in the salvage pathway that produces nicotinamide adenine dinucleotide, or NAD+. Because NAD+ participates in many oxidation-reduction reactions, NMN sits near central metabolic processes. The compound is not a drug in most jurisdictions and is discussed mainly in biochemistry and nutrition research.
The term NMN commonly refers to the beta isomer, in which the nicotinamide group is attached to the ribose through a beta-glycosidic bond. Commercial material may be supplied as the free acid or as a salt, such as a sodium salt, which affects molecular weight and water solubility. Related compounds include nicotinamide riboside and NAD+ itself, but these are distinct molecules with different formulas and cellular handling. Laboratory research often uses the beta form because it matches the naturally occurring configuration found in biological systems.
Nicotinamide mononucleotide, commonly abbreviated NMN, is a naturally occurring nucleotide. Its structure consists of a nicotinamide ring attached to a ribose sugar that carries a phosphate group. The molecular formula is C11H15N2O8P, and the molar mass is about 334.22 grams per mole. In cells, NMN is an intermediate in the salvage pathway that recycles nicotinamide to maintain NAD+ levels. It is not the same compound as NAD+, although it is a direct precursor in one enzymatic step.
Inside cells, the enzyme nicotinamide phosphoribosyltransferase, or NAMPT, converts nicotinamide and a ribose-phosphate donor into NMN. A second enzyme, NMN adenylyltransferase, then converts NMN into NAD+. NAD+ participates in redox reactions and serves as a substrate for signaling enzymes such as sirtuins, PARPs, and CD38. Because NAD+ levels tend to decline with age in many organisms, NMN has drawn interest as a possible way to influence that decline. Whether oral NMN reliably raises NAD+ in human tissues, and whether any such change modifies disease risk, remain open research questions.
== Weblinks == Papierzerfall: Ursachen und Konsequenzen, Prof. Dr. Guido Dessauer, Graz. Frankfurter Forderungen zur Verwendung alterungsbeständiger Papiere für die Buchherstellung Das BücherWiki: Bücher erhalten „Pulverisierung der Kultur. Zu Besuch bei einer Buchrestauratorin“, taz, 27. November 2006 von Gabriele Goettle Näheres zu DIN 9706 und Alterungsbeständigkeit (Lindauer Organisation) Wissensdatenbank der Koordinierungsstelle für die Erhaltung des schriftlichen Kulturguts (KEK)
Edwards Ltd ist ein britischer multinationaler Hersteller von Vakuumpumpen und Abgasmanagementsystemen. Der Hauptsitz des Unternehmens, das seit 2014 zur Atlas Copco Gruppe gehört, befindet sich in Burgess Hill, Großbritannien. Edwards hält 1700 Patente, unter anderem für trockenlaufende (ölfreie) Vakuumpumpen, und stellt Produkte her, die bei der Herstellung von Halbleitern, in der wissenschaftlichen Forschung, bei der Gefriertrocknung und in anderen Branchen eingesetzt werden. Die Vakuumpumpen von Edwards entfernen zum Beispiel Verunreinigungen im Large Hadron Collider des CERN. Die Herstellung erfolgt überwiegend durch Tochterunternehmen in der Tschechischen Republik, Südkorea, den USA und China. Die weltweiten Forschungs- und Entwicklungseinrichtungen von Edwards befinden sich weiterhin im Vereinigten Königreich. Zu den wichtigsten Kunden im Jahr 2012 gehörten Samsung, Hynix, Agilent und LG.
=== Unabhängig (1919–1967) === 1919 gründeten der Physiker und Universitätsdozent Frederick David Edwards und sein Vater William ihr gleichnamiges Unternehmen in Camberwell, London, als Edwards Equipment and Services. Sie verkauften Vakuumpumpen an Forschungslabors im Vereinigten Königreich, in Frankreich, Deutschland und den USA. Als der Zweite Weltkrieg begann, wurden die deutschen Patente im Vereinigten Königreich für ungültig erklärt, was bedeutete, dass Edwards von seinen Zulieferern abgeschnitten war. Deshalb begann das Unternehmen 1939 mit der Herstellung seiner eigenen Produkte. Das Unternehmen wurde 1940 in W Edwards and Co. und 1950 in Edwards High Vacuum International Ltd. umbenannt und zog 1953 von London nach Crawley um. Edwards kaufte 1954 den italienischen Hersteller von Gefriertrocknungsanlagen Alto Vuoto SpA und 1958 das Werk des ehemaligen Subunternehmers J H Holmes and Son Ltd. in Shoreham auf. In den 1960er Jahren ging das Unternehmen an die Börse und litt unter Streiks. Der Gründer FD Edwards starb und nach finanziellen Schwierigkeiten wurde das Unternehmen an BOC verkauft.
Sources: de.wikipedia.org
=== BOC (1968–2006) === Auf den Kauf von Edwards durch die BOC-Gruppe im Jahr 1968 folgten eine internationale Expansion, insbesondere nach Asien, und Investitionen an den Standorten Crawley, Eastbourne, Shoreham und Burgess Hill. 1984 entwickelte und patentierte Edwards die erste praktische trockenlaufende (ölfreie) Hochvakuumpumpe. Das Design wurde vom schnell wachsenden Markt der Halbleiterherstellung übernommen. 1992 kaufte Edwards die Abgasmanagementsysteme von Electrotech Ltd. für die Halbleiterherstellung. Das Unternehmen hatte seinen Sitz in Nailsea, bevor es nach Clevedon, Großbritannien, umzog, um die Umweltschutztechnologie von Edwards in der Halbleiterfertigung zu ergänzen. Vier Jahre später, 1996, wurden neue Anlagen in Burgess Hill eingeweiht. 1997 fusionierte BOC sein Elektronikgasgeschäft mit Edwards zu BOC Edwards. Im selben Jahr erwarb das Unternehmen die Systems Chemistry Inc von der Submicron Systems Corp aus Allentown (USA), einen Anbieter von Managementsystemen für hochreine Chemikalien, die in der Halbleiterherstellung verwendet werden. Das Unternehmen wurde zu Edwards’ Abteilung für Chemikalienmanagement. Allentown, USA. Das Unternehmen wurde Edwards‘ Unternehmensbereich für Chemikalienmanagement. Im Jahr 1999 erwarb Edwards die in Minneapolis ansässige Abteilung von FSI International Inc. für 38 Millionen US-Dollar. Es folgte der Kauf der Vakuumejektor- und Entlüftungseinheiten von Hick Hargreaves, der Wilhelm Klein GmbH, des Kolbenpumpengeschäfts von Stokes und der Hibon Inc. für 12,8 Millionen Pfund von der Smiths Group.
Sources: de.wikipedia.org
NMN stands for nicotinamide mononucleotide. It is a naturally occurring nucleotide and an intermediate in NAD+ biosynthesis.
No. NMN is a precursor that can be converted to NAD+ in cells. NAD+ is the larger dinucleotide that participates in many redox reactions.
Small amounts of NMN have been reported in several foods, including certain vegetables and fruits. The measured levels vary, and the significance of dietary intake is not fully established.
NMN is nicotinamide mononucleotide, a nucleotide intermediate in NAD+ biosynthesis. It occurs naturally in cells and is also produced commercially as a supplement ingredient.